These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

63 related items for PubMed ID: 9402421

  • 1. [ACE-inhibitors indicated even in non-diabetic nephropathy].
    Internist (Berl); 1996 Oct; 37(10 Suppl Ace-hemmer):1-8. PubMed ID: 9402421
    [No Abstract] [Full Text] [Related]

  • 2. Angiotensin converting enzyme inhibition in non-diabetic nephropathy with non-nephrotic proteinuria.
    Pennesi M, Torre G.
    Pediatr Nephrol; 2000 May; 14(5):438. PubMed ID: 10805476
    [No Abstract] [Full Text] [Related]

  • 3. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
    Furumatsu Y, Nagasawa Y, Tomida K, Mikami S, Kaneko T, Okada N, Tsubakihara Y, Imai E, Shoji T.
    Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
    [Abstract] [Full Text] [Related]

  • 4. Transforming growth factor-beta1 is associated with kidney damage in patients with essential hypertension: renoprotective effect of ACE inhibitor and/or angiotensin II receptor blocker.
    Zhu S, Liu Y, Wang L, Meng QH.
    Nephrol Dial Transplant; 2008 Sep; 23(9):2841-6. PubMed ID: 18390891
    [Abstract] [Full Text] [Related]

  • 5. Brief pharmacological intervention in experimental radiation nephropathy.
    Moulder JE, Fish BL, Cohen EP.
    Radiat Res; 1998 Nov; 150(5):535-41. PubMed ID: 9806595
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Renal effects of angiotensin-converting enzyme inhibitors that result in cost savings and improved patient outcomes.
    Swislocki AL, Siegel D.
    Am J Manag Care; 2001 Mar; 7(3):283-95. PubMed ID: 11258145
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [The significance of angiotensin-converting enzyme inhibitors genotype for ACEi response in patients with chronic allograft nephropathy].
    Savin M, Petronić V.
    Srp Arh Celok Lek; 2005 Mar; 133(3-4):194-8. PubMed ID: 16206711
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
    Vogt L, Kocks MJ, Laverman GD, Navis G.
    Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515
    [Abstract] [Full Text] [Related]

  • 18. Therapeutic effects of angiotensin II inhibition or blockade on the progression of chronic renal disease.
    Cantarovich F, Rangoonwala B.
    Int J Clin Pract; 2003 Nov; 57(9):801-22. PubMed ID: 14686572
    [Abstract] [Full Text] [Related]

  • 19. Prediction of chronic renal allograft dysfunction from evaluations of TGFBeta1 and the renin-angiotensin system.
    Yamada K, Hatakeyama E, Arita S, Sakamoto K, Kashiwabara H, Hamaguchi K.
    Clin Exp Nephrol; 2003 Sep; 7(3):238-42. PubMed ID: 14586721
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.